NEW YORK – Bioinformatics firm Massive Bio announced Friday that it has entered into a strategic partnership with Roche subsidiary Foundation Medicine to improve patient enrollment in oncology clinical trials.
The partnership will marry Massive Bio's patient matching technology with Foundation Medicine's next-generation sequencing expertise and healthcare provider network.
The companies will develop integrated solutions that use shared data and artificial intelligence analytics focused on patient matching to "enhance service delivery for both Massive Bio's and Foundation Medicine's customers," Massive Bio said in a statement. The firms will use advanced AI techniques and a digital health platform to refine clinical trial processes.
"The application of real-time AI and our comprehensive data significantly boosts the speed and accuracy of clinical trial matching," Arturo Loaiza-Bonilla, Massive Bio's cofounder and chief medical officer, said in a statement. "This capability allows us to provide individualized treatments more quickly and accurately, enhancing patient outcomes across the globe. Joining forces with Foundation Medicine is pivotal as it will allow us to develop solutions to the cancer clinical trial enrollment paradox."
Massive Bio's Synergy-AI platform analyzes and summarizes extensive medical records, including biomarker data from a variety of sources, to match patients with more than 16,000 clinical trials. The company also uses predictive analytics to reduce screen failures and maximize enrollment potential, it noted.